Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?

被引：7

作者：

Signorelli, Diego ^{[1
]}

Macerelli, Marianna ^{[1
]}

Proto, Claudia ^{[1
]}

Vitali, Milena ^{[1
]}

Cona, Maria Silvia ^{[1
]}

Agustoni, Francesco ^{[1
]}

Zilembo, Nicoletta ^{[1
]}

Platania, Marco ^{[1
]}

Trama, Annalisa ^{[2
]}

Gallucci, Rosaria ^{[1
]}

Ganzinelli, Monica ^{[1
]}

Pelosi, Giuseppe ^{[3
]}

Pastorino, Ugo ^{[4
]}

de Braud, Filippo ^{[1
]}

Garassino, Marina Chiara ^{[1
]}

Lo Russo, Giuseppe ^{[1
]}

机构：

[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Prevent & Predict Med, Milan, Italy

[3] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Lab Med, Milan, Italy

[4] Fdn IRCCS Ist Nazl Tumori, Div Thorac Surg, Milan, Italy

来源：

TUMORI JOURNAL | 2016年 / 102卷 / 01期

关键词：

Chemotherapy; Immunotherapy; Malignant pleural mesothelioma; Target therapy; PHASE-III TRIAL; PEMETREXED PLUS CISPLATIN; PREVIOUSLY TREATED PATIENTS; EUROPEAN-ORGANIZATION; GEMCITABINE TREATMENT; TRIMODALITY THERAPY; PRETREATED PATIENTS; IMATINIB MESYLATE; SUPPORTIVE CARE; CLINICAL-TRIAL;

D O I：

10.5301/tj.5000436

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Malignant pleural mesothelioma is a rare cancer with a cause-effect relationship to asbestos exposure. The prognosis is poor and chemotherapy seems the best treatment option. In the last two decades a deeper understanding of mesothelioma carcinogenesis and invasiveness mechanisms has prompted research efforts to test new agents in patients with malignant pleural mesothelioma, but the results have been modest. Attractive preclinical data disappointed in subsequent experimental phases. Other promising agents failed to improve patient outcomes due to high toxicity. Interesting suggestions have come from preliminary data on immunotherapy. Several trials are ongoing and the results are eagerly awaited. The aim of this review is to discuss the most recent news on systemic therapy for advanced malignant pleural mesothelioma.

引用

页码：18 / 30

页数：13

共 92 条

[31] Phase 1 Study of the Antimesothelin Immunotoxin SS1P in Combination With Pemetrexed and Cisplatin for Front-Line Therapy of Pleural Mesothelioma and Correlation of Tumor Response With Serum Mesothelin, Megakaryocyte Potentiating Factor, and Cancer Antigen 125 [J].

Hassan, Raffit ;

Sharon, Elad ;

Thomas, Anish ;

Zhang, Jingli ;

Ling, Alexander ;

Miettinen, Markku ;

Kreitman, Robert J. ;

Steinberg, Seth M. ;

Hollevoet, Kevin ;

Pastan, Ira .

CANCER, 2014, 120 (21) :3311-3319

[32] Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses [J].

Hegmans, J. P. J. J. ;

Hemmes, A. ;

Hammad, H. ;

Boon, L. ;

Hoogsteden, H. C. ;

Lambrecht, B. N. .

EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (06) :1086-1095

[33] Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma [J].

Jackman, David M. ;

Kindler, Hedy L. ;

Yeap, Below Y. ;

Fidias, Panos ;

Salgia, Ravi ;

Lucca, Joan ;

Morse, Linda K. ;

Ostler, Patricia A. ;

Johnson, Bruce E. ;

Janne, Pasi A. .

CANCER, 2008, 113 (04) :808-814

[34]

Jänne PA, 2006, J THORAC ONCOL, V1, P506

[35] Vatalanib in malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B (CALGB 30107) [J].

Jahan, Thierry ;

Gu, Lin ;

Kratzke, Robert ;

Dudek, Arkadiusz ;

Otterson, Gregory A. ;

Wang, Xiaofei ;

Green, Mark ;

Vokes, Everett E. ;

Kindler, Hedy Lee .

LUNG CANCER, 2012, 76 (03) :393-396

[36] Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma [J].

Jassem, Jacek ;

Ramlau, Rodryg ;

Santoro, Armando ;

Schuette, Wolfgang ;

Chemaissani, Assad ;

Hong, Shengyan ;

Blatter, Johannes ;

Adachi, Susumu ;

Hanauske, Axel ;

Manegold, Christian .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1698-1704

[37] The predictive role of serum VEGF in an advanced malignant mesothelioma patient cohort treated with thalidomide alone or combined with cisplatin/gemcitabine [J].

Kao, Steven Chuan-Hao ;

Harvie, Rozelle ;

Paturi, Florian ;

Taylor, Robyn ;

Davey, Ross ;

Abraham, Rick ;

Clarke, Stephen ;

Marx, Gavin ;

Cullen, Martin ;

Kerestes, Zoltan ;

Pavlakis, Nick .

LUNG CANCER, 2012, 75 (02) :248-254

[38] Carboplatin Plus Pemetrexed as First-line Treatment of Patients With Malignant Pleural Mesothelioma: A Phase II Study [J].

Katirtzoglou, Nikolaos ;

Gkiozos, Ioannis ;

Makrilia, Nektaria ;

Tsaroucha, Emilia ;

Rapti, Aggeliki ;

Stratakos, Grigorios ;

Fountzilas, Georgios ;

Syrigos, Konstantinos N. .

CLINICAL LUNG CANCER, 2010, 11 (01) :30-35

[39] Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma [J].

Kindler, Hedy L. ;

Karrison, Theodore G. ;

Gandara, David R. ;

Lu, Charles ;

Krug, Lee M. ;

Stevenson, James P. ;

Jaenne, Pasi A. ;

Quinn, David I. ;

Koczywas, Marianna N. ;

Brahmer, Julie R. ;

Albain, Kathy S. ;

Taber, David A. ;

Armato, Samuel G., III ;

Vogelzang, Nicholas J. ;

Chen, Helen X. ;

Stadler, Walter M. ;

Vokes, Everett E. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (20) :2509-2515

[40] Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) [J].

Kindler, Hedy Lee ;

Niedzwiecki, Donna ;

Hollis, Donna ;

Sutherland, Susan ;

Schrag, Deborah ;

Hurwitz, Herbert ;

Innocenti, Federico ;

Mulcahy, Mary Frances ;

O'Reilly, Eileen ;

Wozniak, Timothy F. ;

Picus, Joel ;

Bhargava, Pankaj ;

Mayer, Robert J. ;

Schilsky, Richard L. ;

Goldberg, Richard M. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3617-3622

← 1 2 3 4 5 6 7 8 9 10 →